Search Result

Results for "

inactive+control

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (1) Aurora Kinase (1) EGFR (1) Elastase (1) Epigenetic Reader Domain (3) GCGR (1) HPV (1) iGluR (2) JNK (1) MAGL (1) Necroptosis (1) NF-κB (1) PKC (1) Protein Arginine Deiminase (1) Reference Standards (1) Sirtuin (1) TGF-β Receptor (2) WDR5 (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107477

GSK8573	Epigenetic Reader Domain	Cancer
GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a K_d value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .

HY-121954

*Necrostatin-1 (inactive control)* Nec-1 (inactive control)	Necroptosis	Cancer
Necrostatin-1 (Nec-1) (inactive control) is an inactive analog of Necrostatin-1 (HY-15760). Necrostatin-1 is a potent necroptosis inhibitor .

HY-16994

OICR-0547	WDR5	Cancer
OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .

HY-120343

GSK106	Protein Arginine Deiminase	Cardiovascular Disease Inflammation/Immunology Cancer
GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 .

HY-P3970D

KQFK TFA	TGF-β Receptor	Inflammation/Immunology
KQFK TFA is the TFA salt form of KQFK (HY-P3970C). KQFK TFA is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .

HY-125143

ABC34	MAGL	Metabolic Disease
ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both ABHD6 and PPT122 .

HY-P1402

[Glu27]-PKC (19-36)	PKC	Others
[Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .

HY-P2243

D-JBD19	JNK	Neurological Disease
D-JBD19 is an impermeable peptide that serves as an inactive control for the JNK inhibitor D-JNKI1 (HY-P0069). D-JNKI1 has neuroprotective effects .

HY-111457

BAY-677 1 Publications Verification	Elastase	Inflammation/Immunology
BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC₅₀ of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .

HY-118914

Glucagon receptor antagonist inactive control	GCGR
Glucagon receptor antagonist inactive control (Compound 2) is a compound structurally similar to the glucagon receptor (GCGR) antagonist Glucagon receptor antagonist (Compound 1) but lacks antagonistic activity against glucagon receptor (GCGR). Glucagon receptor antagonist inactive control can be used as a negative control to study mechanisms related to glucagon receptor-mediated signaling pathways .

HY-119857

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .

HY-113894

Retreversine	Aurora Kinase	Cancer
Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .

HY-129253

GSK984	HPV	Infection
GSK984 is an inactive control probe for GSK983 (HY-119098), a dihydroorotate dehydrogenase (DHODH) inhibitor with antiviral activity .

HY-P2670

SN50M	NF-κB	Others
SN50M, a mutant peptide of SN50 (HY-P0151), is a cell membrane-permeable inactive control peptide .

HY-P3970C

KQFK	TGF-β Receptor	Others
KQFK is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .

HY-153887

HyT36(-Cl)	EGFR	Others
HyT36(-Cl) is the inactive control compound of HyT36, a small molecule hydrophobic tag compound that can be used in protein folding research .

HY-P3882

Fmoc-Ala-Glu-Gln-Lys-NH2	Amino Acid Derivatives	Neurological Disease
Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein .

HY-101125B

D-Moses D-45	Epigenetic Reader Domain	Cancer
D-Moses (D-45) is an enantiomer of L-Moses (HY-101125). L-Moses (L-45) is a potent and selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor. D-Moses shows no observable binding for PCAF Brd. D-Moses can be used as an inactive control compound to L-Moses .

HY-P1057

Pep4c	iGluR	Neurological Disease
Pep4c is an inactive control peptide for Pep2m (HY-P1058). Pep4c lacks functional activity to disrupt Protein Interacting with C Kinase 1 (PICK1)-AMPA receptor (GluA2) or N-ethylmaleimide-sensitive factor (NSF)-GluA2 interactions. Pep4c is used as a negative control in experiments to validate the specificity of Pep2m's effects on AMPA receptor trafficking and synaptic plasticity ^{[1] [2] [3] [4] [5] [6]}.

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

HY-107477R

GSK8573 (Standard)	Reference Standards Epigenetic Reader Domain	Cancer
GSK8573 (Standard) is the analytical standard of GSK8573 (HY-107477). This product is intended for research and analytical applications. GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a K_d value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .

Cat. No.	Product Name	Target	Research Area

HY-P3970D

KQFK TFA	TGF-β Receptor	Inflammation/Immunology
KQFK TFA is the TFA salt form of KQFK (HY-P3970C). KQFK TFA is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .

HY-P1402

[Glu27]-PKC (19-36)	PKC	Others
[Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .

HY-P2243

D-JBD19	JNK	Neurological Disease
D-JBD19 is an impermeable peptide that serves as an inactive control for the JNK inhibitor D-JNKI1 (HY-P0069). D-JNKI1 has neuroprotective effects .

HY-P2670

SN50M	NF-κB	Others
SN50M, a mutant peptide of SN50 (HY-P0151), is a cell membrane-permeable inactive control peptide .

HY-P3970C

KQFK	TGF-β Receptor	Others
KQFK is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .

HY-P3882

Fmoc-Ala-Glu-Gln-Lys-NH2	Amino Acid Derivatives	Neurological Disease
Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein .

HY-P1057

Pep4c	iGluR	Neurological Disease
Pep4c is an inactive control peptide for Pep2m (HY-P1058). Pep4c lacks functional activity to disrupt Protein Interacting with C Kinase 1 (PICK1)-AMPA receptor (GluA2) or N-ethylmaleimide-sensitive factor (NSF)-GluA2 interactions. Pep4c is used as a negative control in experiments to validate the specificity of Pep2m's effects on AMPA receptor trafficking and synaptic plasticity ^{[1] [2] [3] [4] [5] [6]}.

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.